Abstract: The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an amount sufficient to attenuate expression of a target gene by an RNA interference mechanism, e.g., in a sequence-dependent, PKR-independent manner. In particular, the subject method can be used to alter the growth, survival or differentiation of cells for therapeutic and cosmetic purposes.

Abstract: A system and method for creating a localized silence area. A mobile device may be registered with an access point base station. Any direct communication links from the mobile device to any other base stations may be removed. An indication may be given to the mobile device that the mobile device is in a localized silence zone. The indication may include a request that the mobile device operate in a silent mode, information about making outgoing calls, information about receiving incoming calls, or a combination of these. Procedures for incoming voice calls to the mobile device may be different for different priority levels.

Abstract: Micro-cavity resonant sensors have outer surfaces that are functionalized using click chemistry, e.g., involving a cycloaddition reaction of an alkyne functional group and an azide functional group. A first polymer linking element binds to an outer surface of the micro-cavity and has an azide functional group, which bonds to an alkyne functional group of a second polymer linking element as a result of a cycloaddition reaction. A functionalization element such as an antibody, antigen or protein for sensing a target molecule is bound to the second linking element.

Abstract: The present application relates to inhibitors of ribonucleotide reductase subunit 2 (R2), and methods and compositions related to the R2 inhibitors. In certain embodiments, the R2 inhibitors include nucleic acids, such as for example siRNAs.

Abstract: The present invention is directed generally to a layered polymeric monofilament fiber drug delivery device, where each layer of the device can contain a different polymer, drug, additive, or any combination or mixture thereof. The layered nature of the current monofilament polymeric monofilament device provides the capability to modulate the release of one or more drugs and/or the mechanical properties of the fiber so that drug release and device failure can be separately tuned to provide for the tailored introduction of therapeutically effective drugs or agents to a target tissue. Moreover, the fiber may comprise more than one distinct segments along its length, each segment itself having different combinations and/or numbers of layers thereby providing even greater freedom in the design of the therapeutic delivery device. The invention is also directed to a method of manufacturing such a layered polymeric monofilament fiber drug delivery device, and methods of treatment using such devices.

Abstract: A bowling lane maintenance machine utilizes flexible wick segments to transfer lane dressing to the applicator roll of the machine. The wick segments are caused to flex into and out of contacting engagement with a transfer roll associated with the applicator roll by rotatable cams that engage cam followers associated with the wick segments. The cams are all secured to a common cam shaft and are rotated in unison through successive short segments of rotational travel by an indexing motor that responds to a controller. Each wick segment has at least one spring that urges the segment into contacting engagement with the transfer roll, while the cam for that segment is disposed to engage the follower and flex the wick segment off the transfer roll against the action of the spring when the lobe of the cam is in contacting engagement with the follower.

Abstract: Automatic provisioning of an access point base station or femtocell. The method may include the femtocell transmitting first information (e.g., location information, signal measurement information, capability information, etc.) to a service provider (e.g., over an IP network). The femtocell may receive second information from the service provider, where the second information includes one or more operational parameters. The operational parameters may include hand-off parameters, admission policy parameters, PN or scrambling codes, power parameters, and/or other parameters. The femtocell may operate according to the received parameters to provide access for a plurality of access terminals in a local area.

Abstract: Automatic provisioning of an access point base station or femtocell. The method may include the femtocell transmitting first information (e.g., location information, signal measurement information, capability information, etc.) to a service provider (e.g., over an IP network). The femtocell may receive second information from the service provider, where the second information includes one or more operational parameters. The operational parameters may include hand-off parameters, admission policy information, PN or scrambling codes, power parameters, and/or other parameters. The femtocell may operate according to the received parameters to provide access for a plurality of access terminals in a local area.

Abstract: Automatic provisioning of an access point base station or femtocell. The method may include the femtocell transmitting first information (e.g., location information, signal measurement information, capability information, etc.) to a service provider (e.g., over an IP network). The femtocell may receive second information from the service provider, where the second information includes one or more operational parameters. The operational parameters may include hand-off parameters, admission policy parameters, PN or scrambling codes, power parameters, and/or other parameters. The femtocell may operate according to the received parameters to provide access for a plurality of access terminals in a local area.

Abstract: Automatic provisioning of an access point base station or femtocell. The method may include the femtocell transmitting first information (e.g., location information, signal measurement information, capability information, etc.) to a service provider (e.g., over an IP network). The femtocell may receive second information from the service provider, where the second information includes one or more operational parameters. The operational parameters may include hand-off parameters, admission policy parameters, PN or scrambling codes, power parameters, and/or other parameters. The femtocell may operate according to the received parameters to provide access for a plurality of access terminals in a local area.

Abstract: Time synchronization of an access point base station. The method may include receiving an assignment message from a service provider comprising a plurality of parameters. The plurality of parameters may include an access point base station frequency assignment, a network identifier, an access point base station identifier, a neighbor list, a PN offset, and/or a scrambling code. The access point base station may then synchronize with the macro base station. Synchronizing may include searching for a strongest macro base station in the neighbor list, synchronizing a long code of the access point base station to the macro base station, estimating a propagation delay between the macro base station and the access point base station, and initializing a state of the access point base station PN code using the propagation delay to provide system time synchronization.

Abstract: A method of preparing a supramolecular complex containing at least one therapeutic agent and a multi-dimensional polymer network is described. A supramolecular complex prepared by a method of the invention is described. A method of treatment by administering a therapeutically effective amount of a supramolecular complex of the invention is also described. Such a supramolecular complex may be used as a delivery vehicle for various therapeutic agents.

Abstract: The present invention relates to improving, at least in part, a deficiency in dark adaptation for an individual. The therapy for dark adaptation includes local administration of a retinoid, such as a Vitamin A or a derivative thereof, such that deleterious side effects seen with systemic administration are avoided.

Abstract: The present invention provides polymers which substantially degrade in the presence of one or more triggers, preferably light energy or hydrogen peroxide, but does not substantially degrade in the absence of one or more triggers.

Abstract: The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an amount sufficient to attenuate expression of a target gene by an RNA interference mechanism. In particular, the RNAi constructs may include one or more modifications to improve serum stability, cellular uptake and/or to avoid non-specific effect. In certain embodiments, the RNAi constructs contain an aptamer portion. The aptamer may bind to human serum albumin to improve serum half life. The aptamer may also bind to a cell surface protein that improves uptake of the construct.

Abstract: The present application relates to inhibitors of ribonucleotide reductase subunit 2 (R2), and methods and compositions related to the R2 inhibitors. In certain embodiments, the R2 inhibitors include nucleic acids, such as for example siRNAs.

Abstract: A grill handle and light assembly is disclosed, the handle being attached to the lid of the grill and the light being detachably secured to the handle for use while grilling or, when detached, as an auxiliary light.

Abstract: The present invention relates to novel compositions comprising polymeric moieties covalently attached to therapeutic agents, wherein the therapeutic agent is attached to the polymeric moiety through a tether. By selecting from a variety of tether groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein.

Abstract: A method of preparing a supramolecular complex containing at least one therapeutic agent and a multi-dimensional polymer network is described. A supramolecular complex prepared by a method of the invention is described. A method of treatment by administering a therapeutically effective amount of a supramolecular complex of the invention is also described. Such a supramolecular complex may be used as a delivery vehicle for various therapeutic agents.

Abstract: A bowling lane maintenance machine, after completing a maintenance operation on one lane, moves onto the approach behind the foul line, turns and indexes over to the next lane, then turns again and moves up to the foul line of the next lane. Preferably, the machine is self-indexing so that all operations are carried out without operator intervention. Left and right wheels that drive the machine on the approach can be driven at relatively different speeds and in opposite directions to enable the machine to turn about a zero radius.